ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

0RIS Circio Holding Asa

15.98
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Circio Holding Asa LSE:0RIS London Ordinary Share NO0013033795 CIRCIO HOLDING ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.98 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Home Health Care Services 10M -432.9M -2.2969 -6.96 3.01B

Targovax to Host Capital Markets Day 15 October 2018, in Oslo, Norway

04/10/2018 6:15am

PR Newswire (US)


Circio Holding Asa (LSE:0RIS)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Circio Holding Asa Charts.

Presentation of full TG01 phase I/II clinical trial results in resected pancreatic cancer, by Professor Daniel Palmer

Update on the TG mutRAS neoantigen vaccine development strategy

Review of recent ONCOS-102 interim data in melanoma and mesothelioma

OSLO, Norway, Oct. 4, 2018 /PRNewswire/ --

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces that it will host a Capital Markets Day in Oslo on Monday 15 October 2018, from 08:30 – 10:30 

The event will include a presentation by a world leading expert on pancreatic cancer, Professor Daniel Palmer, who is the Chair of Medical Oncology at the University of Liverpool and Clatterbridge Cancer Centre. Professor Palmer has been involved in a number of large international clinical studies in pancreatic cancer, and was the Principal Investigator of Targovax's TG01 phase I/II trial in resected pancreatic cancer, in combination with adjuvant gemcitabine. Top-line survival data from the trial were released in May 2018 (see press release here) and at the upcoming event Professor Palmer will present the full study results.

Øystein Soug, CEO of Targovax, will give an update on the TG mutRAS neoantigen vaccine development strategy.

There will also be an update on the ongoing ONCOS oncolytic virus program, including a review of recent interim read-outs from the ONCOS-102 clinical trials in mesothelioma and melanoma, by Magnus Jäderberg, CMO of Targovax.

Event venue: Hotel Continental, Oslo, Norway
Date: 15 October 2018
Time: 08:30 – 10:30 CET

A live webcast of the symposium will be available in the Events and Presentations section of the Targovax website.

To register for the event, please contact renate.birkeli@targovax.com.

CONTACT:

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/targovax/r/targovax-to-host-capital-markets-day-15-october-2018--in-oslo--norway,c2634755

 

Copyright 2018 PR Newswire

1 Year Circio Holding Asa Chart

1 Year Circio Holding Asa Chart

1 Month Circio Holding Asa Chart

1 Month Circio Holding Asa Chart

Your Recent History

Delayed Upgrade Clock